islatravir prodrug (BRII-732)
/ Brii Biosci
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
April 27, 2025
Two phase 1 studies of safety, tolerability, and pharmacokinetics of an EFdA prodrug (BRII-732) in healthy adult participants.
(PubMed, Antimicrob Agents Chemother)
- "Tablet and solution formulations exhibited comparable systemic exposure. These studies highlight the favorable safety, tolerability, and pharmacokinetic profile of once weekly BRII-732 in healthy adult participants."
Clinical • Journal • P1 data • PK/PD data • Human Immunodeficiency Virus • Infectious Disease
September 08, 2022
Safety, Tolerability, and Pharmacokinetics of BRII-732, A Medoxomil Carbonate Prodrug of Islatravir in Healthy Adult Subjects
(IDWeek 2022)
- No abstract available
Clinical • PK/PD data • Infectious Disease
September 08, 2022
Safety, Tolerability, and Pharmacokinetics of BRII-732, A Medoxomil Carbonate Prodrug of Islatravir in Healthy Adult Subjects
(IDWeek 2022)
- No abstract available
Clinical • PK/PD data • Infectious Disease
1 to 3
Of
3
Go to page
1